Glaxosmithkline Biologicals Sa

Smithkline Beecham Biologicals S.a.

Brigitte Desiree Alberte Colau

Vincent Vande Velde

Francoise Denamur

Isabelle Knott

Annick Poliszczak

Nigel Maurice Harford

Jean Didelez

Georges Thiry

Beatrice Arsene Virginie De Vos

The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further provides a novel formulation for a rotavirus vaccine which is in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue.

Homogeneous attenuated human rotavirus population

Immunogenic composition of a homogeneous live attenuated human rotavirus population

The invention provides a method of inducing an immune response against rotavirus infection from one rotavirus serotype, the method comprising administering to a subject a composition comprising an attenuated rotavirus vaccine from a different serotype. There is in particular provided a method of inducing an immune response against rotavirus infection from a non-G1 serotype, the method comprising administering to a subject a composition comprising an attenuated rotavirus vaccine from a G1 serotype.

Immunization with an attenuated human rotavirus

Vaccine

A new mumps vaccine is presented, comprising a homogeneous pure isolate derived from the Jeryl-Lynn strain of mumps virus. In a preferred embodiment of the invention the vaccine produces higher seroconversion and anitbody titres than know commercial vaccines.

Vaccine against mumps containing a jeryl-lynn virus strain

A new mumps vaccine is presented, comprising a homogeneous pure isolate derived from the Jeryl-Lynn strain of mumps virus.

Vaccine against Mumps containing a Jeryl-Lynn virus strain

Growing community of inventors

Rixensart, Belgium

Brigitte Desiree Alberte Colau